MARKET

THTX

THTX

Theratechnologies Inc
NASDAQ
1.500
-0.170
-10.18%
After Hours: 1.522 +0.022 +1.43% 19:51 03/28 EDT
OPEN
1.610
PREV CLOSE
1.670
HIGH
1.640
LOW
1.500
VOLUME
839.28K
TURNOVER
--
52 WEEK HIGH
2.180
52 WEEK LOW
1.080
MARKET CAP
68.97M
P/E (TTM)
-8.9127
1D
5D
1M
3M
1Y
5Y
1D
Theratechnologies rises after FDA label expansion for best seller Egrifta
Seeking Alpha · 4d ago
U.S.-LISTED SHARES OF THERATECHNOLOGIES UP 23% AFTER FDA APPROVES NEW TREATMENT FOR ABDOMINAL FAT IN HIV PATIENTS
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Chewy, V2X, Cintas
Reuters · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Theratechnologies (THTX), KalVista Pharmaceuticals (KALV) and Mereo Biopharma Group Plc (MREO)
TipRanks · 4d ago
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
Benzinga · 4d ago
BUZZ-Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar
Reuters · 4d ago
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
Futures Flat Awaiting Clarity on Tariffs
Barchart · 4d ago
More
About THTX
More
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Recently
Symbol
Price
%Change

Webull offers Theratechnologies Inc stock information, including NASDAQ: THTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THTX stock methods without spending real money on the virtual paper trading platform.